🔗 Share this article

While the US continues making historic changes to its immunization schedules, one figure appears unexpectedly: Høeg, a US-based sports physician and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccinations throughout the pandemic and has focused upon alleged deaths following COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Program

Public health authorities were set to announce sweeping revisions to the childhood vaccination calendar recently, bringing the US with Denmark’s vaccine program, it is understood – a major change that would place the US at odds with a large portion of the world with insufficient data for improved outcomes. The announcement has been delayed until the new year.

Rather than Vinay Prasad, Høeg is set to present at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

A Shift at the Agency

Høeg's temporary position might represent a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has often pushed for ending specific pediatric shot schedules in the US so as to align more in line with Denmark's approach, a country with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccines – traditionally the purview of Prasad, chief of the FDA’s CBER – rather than medication approval.

Concerns Over Background

The appointee has no apparent experience in pharmaceutical research, oversight or leadership, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for running the drug-regulation department, stated Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a large organization. She has no expertise in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with legal statutes and the research of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that previous people who ran CBER have had.”

The drug center has an immense range of responsibilities at the agency, Woodcock emphasized.

“The public just pays attention on the novel medication approvals, but the generic program clears thousands of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and all of those need to be looked after,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a significant leadership component to the position, which supervises more than 5,000 employees. “It’s a enormous management job, if you do it right,” Woodcock concluded.

Official Statement and Disputed Programs

When asked about inquiries about Dr. Høeg's qualifications and whether this selection represents greater collaboration among FDA leaders on immunizations, a representative said that the “concerns rely on incorrect premises”.

“Her experience matches the functions of her position,” the representative explained, citing the period Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a controversial rapid therapy clearance system that allegedly concerned her predecessors. “By what process are these medications being chosen for this expedited pathway? Who is making the calls?” Dr. Howard asked. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards more relaxed oversight of most medications, aside from vaccines.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a clearer, if troubling, past, critics have noted. She published a study using unverified volunteer-provided data to assess the incidence of heart inflammation after COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the new government included altering rules for novel immunizations and halting “optional” vaccines, she said after the election on a audio program. At the FDA, Høeg has according to sources proposed barring adolescent males from receiving COVID-19 vaccines.

“She is an all-around true believer who commences with her conclusions and tailors the evidence to fit the evidence in a very deceptive, dishonest manner,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other dissenters, {like|